Format

Send to

Choose Destination
Methods Mol Biol. 2011;793:495-508. doi: 10.1007/978-1-61779-328-8_32.

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

Author information

1
Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA.

Abstract

Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models.

PMID:
21913121
PMCID:
PMC3548622
DOI:
10.1007/978-1-61779-328-8_32
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center